Abstract:Rationale The blood pressure value below which the benefits of vasopressors clearly outweigh their disadvantages is uncertain. Objectives The main objective of this analysis was to investigate the statistical properties and potential utility of indices estimating the vasopressor dose-rates as a function of blood pressure values over time. Methods In this single-center observational study, we collected blood pressure values from intensive care unit (ICU) monitors and norepinephrine dose-rates from infusion pumps corresponding to a derivation and a validation cohort. Patients included in each cohort were 18 years or older and received norepinephrine in the ICU. We defined and derived indices corresponding to vasopressor therapy above (>65 mmHg) and below (<60 mmHg) targets. We report the distribution of both indices over time from both cohorts as well as their associations with hospital mortality using logistic regression models adjusted for baseline variables. Results Between July 30 2020 and March 28 2022, 283 patients were included in the derivation cohort. The median ICU stay was 5 days (interquartile range [IQR] 2, 10.5) and the median duration of norepinephrine therapy was 27.3 hours (IQR 13.9, 54.2). The median cumulative time with a MAP below 60 mmHg was 0.9 hours (IQR 0.2, 3.1), whereas the cumulative time with a MAP above 65 mmHg was 22.5 hours (IQR 10.9, 40.4). Adjusting for prespecified baseline variables, the above target index was associated with hospital mortality (OR 1.6 , 95% CI 1.2, 2.3) but not the below target index (OR 1.1 95% CI 0.8, 1.5). Between May 5 2022 and December 16 2022, 83 patients were included in the validation cohort. The duration of ICU stay and the proportion of norepinephrine exposure above MAP target were consistent with the derivation cohort. The point estimates of the associations between each index and mortality were also consistent with the derivation cohort, but not statistically significant. Conclusion Indices of vasopressor administration as a function of blood pressure suggest that during most of vasopressor therapy episodes, patients are treated above target. The association of these indices with patient outcomes remains uncertain but could be explored in larger datasets, and future clinical trials of target MAPs may consider measurement of these indices to adjust results for treatment adherence.

What problem does this paper attempt to address?

The key problem that this paper attempts to solve is to determine whether the benefits of vasopressors (such as norepinephrine) are significantly greater than their side effects when the blood pressure value is below a certain threshold (for example, 60 mmHg) in the intensive care unit (ICU). In addition, the study also aims to explore the statistical characteristics and potential utility of indices that combine vasopressor doses and blood pressure values over time (i.e., the "MAP - vasopressor index"), which can more accurately reflect clinical decision - making, and evaluate the association between these indices and in - hospital mortality of patients. Specifically, the main objectives of the study are: 1. **Define and validate the "MAP - vasopressor index"**: These indices combine the changes in vasopressor doses and blood pressure values (above 65 mmHg or below 60 mmHg) over time to more precisely reflect the achievement of specific blood pressure targets during the clinical treatment process. 2. **Evaluate the relationship between these indices and in - hospital mortality**: Analyze the relationship between these indices and in - hospital mortality through a multivariate logistic regression model after adjusting for baseline variables. 3. **Explore the impact of different data collection frequencies on index calculation**: Compare the correlation between the indices calculated from high - resolution data (collected every 5 seconds) and low - resolution data (collected every hour) to evaluate the impact of data collection frequencies on the results. Through these objectives, the study hopes to provide more precise tools for future clinical trials, so as to better adjust the use strategy of vasopressors and thus improve the prognosis of patients.

Derivation and validation of indices incorporating vasopressor dose and blood pressure values over time

Pooled analysis of higher versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock

Blood pressure targets for vasopressor therapy: a systematic review

Associations Between Elevated Systolic Blood Pressure and Outcomes in Critically Ill Patients: A Retrospective Cohort Study and Propensity Analysis

Prior Exposure to Angiotensin II Receptor Blockers in Patients With Septic Shock to Individualize Mean Arterial Pressure Target? A Post Hoc Analysis of the Sepsis and Mean Arterial Pressure (SEPSISPAM) Trial

Noradrenaline dose cutoffs to characterise the severity of cardiovascular failure: Data‐based development and external validation

Renin Levels and Angiotensin II Responsiveness in Vasopressor-Dependent Hypotension

Impact of Blood Pressure Targets in Patients With Heart Failure Undergoing Postresuscitation Care: A Subgroup Analysis From a Randomized Controlled Trial

Blood pressure response index and clinical outcomes in patients with septic shock: a multicenter cohort study

INITIATION TIMING OF VASOPRESSOR IN PATIENTS WITH SEPTIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS

Accuracy of Noninvasive Blood Pressure Monitoring in Critically Ill Adults

The Vasopressin Loading for Refractory septic shock (VALOR) study: a prospective observational study

Norepinephrine weaning guided by the Hypotension Prediction Index in vasoplegic shock after cardiac surgery: protocol for a single-centre, open-label randomised controlled trial - the NORAHPI study

Radial artery pressure monitoring underestimates central arterial pressure during vasopressor therapy in critically ill surgical patients

Hypotension During Vasopressor Infusion Occurs in Predictable Clusters: A Multicenter Analysis

The effect of vasopressor agents on pressure injury development in intensive care patients

Prognostic evaluation of the norepinephrine equivalent score and the vasoactive-inotropic score in patients with sepsis and septic shock: a retrospective cohort study

Safety and efficacy of peripheral versus centrally administered vasopressor infusion: A single-centre retrospective observational study

International pharmacy survey of peripheral vasopressor infusions in critical care (INFUSE)

Prospective randomized double-blind study to evaluate the superiority of Vasopressin versus Norepinephrine in the management of the patient at renal risk undergoing cardiac surgery with cardiopulmonary bypass (NOVACC trial)

Peripherally administered vasopressors in critically ill adult patients: A survey of UK healthcare professional practices, attitudes and experiences